share_log

Guggenheim Initiates Coverage On Precision BioSciences With Buy Rating, Announces Price Target of $19

Benzinga ·  Apr 30 07:41

Guggenheim analyst Debjit Chattopadhyay initiates coverage on Precision BioSciences (NASDAQ:DTIL) with a Buy rating and announces Price Target of $19.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment